



Numiera Therapeutics

STALLING THE ENGINES OF CANCER CELLS

Corporate Overview

Q2 2025



Glioblastoma is an aggressive primary brain tumor


34,000 newly-diagnosed cases annually across the US + EU

Glioblastoma is a high-grade malignancy

- Median patient survival of 12 months with surgery and radiotherapy
- Addition of the chemotherapy drug temozolomide increases median survival by only 2-3 months

Only one therapy has reached market and benefited patients in 50 years

New treatment options are desperately needed to extend survival time






The metabolism of fatty acids is critical for tumor growth

Society for Neuro Oncology Translational Research Award 2016


- Human glioma cells express the necessary enzymes to make energy via fatty acid metabolism
- High expression of these enzymes in the tumor directly correlates with poor disease prognosis
- Blocking this metabolic pathway (with etomoxir) slows the growth of glioma cells




Human glioma cells

Preclinical Data with Lead Small Molecule

CONTROL 75 days post-implantation of glioma cells, significant tumor growth is observed in mice under MRI.



TREATED 75 days post-implantation of glioma cells, no tumor growth is observed in mice under MRI.






This metabolic vulnerability presents a druggable target

A first-in-class small-molecule CPT1 inhibitor, building on 20+ years of drug development

Cancer cells require energy to support malignant growth and recover from chemotherapy

Our drug blocks the rate-limiting step in fatty acid metabolism (CPT1)

Chemotherapy damages DNA



Standard of Care: Temozolomide

Drug blocks energy production needed for repair and replication



Lead Small Molecule: Etomoxir



Competitive advantages

Introducing a new oncology drug




Specific targeting of cancer cells



No viable compensatory mechanism



Comprehensive CMC-pharm-tox dataset



Independently replicated preclinical efficacy data



Orphan Designation already secured



World-class clinical trial site selected




Competitive Landscape

Numiera's orphan drug designation for etomoxir provides 7 years of post-approval market exclusivity

Primary Competitor: Temozolomide (Temodar) gives glioblastoma patients 2-3 extra months, has serious side effects, and is currently the standard of care

Bevacizumab (Avastin) is effective at treating colorectal cancer and non-small-cell lung cancer, but not glioblastoma, although it is often prescribed for neuro oncology patients anyway

Modifi, a Yale University spinout founded in 2021, has shown preclinical efficacy for a new class of temozolomide analogs for neuro oncology indications




¹ Cancer Research UK; ² STATISTICA; ³ REUTERS..



Intellectual property portfolio


Significant opportunity for patent portfolio expansion





Development timeline


Optimized fast-track timeline with significant near-term value-inflection points





Investment opportunity

With incentives from Colorado's Office of Economic Development (OEDIT) and anticipated SBIR grant support



Planned Use of Funds

Corporate Development

- Expand intellectual property portfolio
- Foster strategic partnerships

Clinical Development

- Submit Investigational New Drug Application
- Manufacture product for clinical trials
- Sponsor patient education and recruitment
- Run early-phase clinical trials

Corporate structure



Leadership Team

Izi Stoll, PhD
Founder/CEO



John Nieland, PhD
Product Strategy



Josh Pan, PhD MBA
Business Strategy




Karl Nicholls, CPA
Financial Strategy



Gordon Beck, PhD
Corporate Strategy



Megan Halloran, PhD
Comms Strategy



WESTERN INSTITUTE
FOR ADVANCED STUDY



WESTERN INSTITUTE
FOR ADVANCED STUDY

Supporting Organizations



Additional Partners

Patrick Wen, MD
Clinical Consultant

Vicki Abbas, RN
Clinical Operations

Dustin Key, MA
Clinical Data Management



Thank you



Numiera Therapeutics

STALLING THE ENGINES OF CANCER CELLS

Let's talk more:
partnerships@numiera.com